Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study.
Mycobacterium tuberculosis
extensively drug-resistant tuberculosis
fluoroquinolone
pre-extensively drug-resistant tuberculosis
second-line injectable drugs
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
11
2020
accepted:
06
01
2021
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
26
3
2021
Statut:
epublish
Résumé
Due to the emergence of Drug-resistant (DR) M.tb isolates collected from 2012 to 2017 were tested using sequencing and phenotypic drug susceptibility testing. Genotypes were determined to explore their links with SLD resistance patterns. Of the 272 DR M.tb isolates, 6 non-multidrug resistant (non-MDR) isolates were fluoroquinolones (FQ)-resistant, 3 were XDR and 16 were pre-XDR (14 resistant to FQ and 2 to second-line injectable drugs). The most frequent mutations in FQ-resistant and second-line injectable drugs resistant isolates were This is the first description of SLD resistance in Cambodia. The data suggest that the proportion of XDR and pre-XDR isolates remains low but is on the rise compared to previous reports. The characterization of the XDR+ isolate in a patient who refused treatment underlines the risk of transmission in the population. In addition, genotypic results show, as expected, that the Beijing family is the main involved in pre-XDR and XDR isolates and that the spread of the Beijing pre-XDR strain is capable of evolving into XDR strain. This study strongly indicates the need for rapid interventions in terms of diagnostic and treatment to prevent the spread of the pre-XDR and XDR strains and the emergence of more resistant ones.
Sections du résumé
BACKGROUND
BACKGROUND
Due to the emergence of
METHODS
METHODS
Drug-resistant (DR) M.tb isolates collected from 2012 to 2017 were tested using sequencing and phenotypic drug susceptibility testing. Genotypes were determined to explore their links with SLD resistance patterns.
RESULTS
RESULTS
Of the 272 DR M.tb isolates, 6 non-multidrug resistant (non-MDR) isolates were fluoroquinolones (FQ)-resistant, 3 were XDR and 16 were pre-XDR (14 resistant to FQ and 2 to second-line injectable drugs). The most frequent mutations in FQ-resistant and second-line injectable drugs resistant isolates were
CONCLUSION
CONCLUSIONS
This is the first description of SLD resistance in Cambodia. The data suggest that the proportion of XDR and pre-XDR isolates remains low but is on the rise compared to previous reports. The characterization of the XDR+ isolate in a patient who refused treatment underlines the risk of transmission in the population. In addition, genotypic results show, as expected, that the Beijing family is the main involved in pre-XDR and XDR isolates and that the spread of the Beijing pre-XDR strain is capable of evolving into XDR strain. This study strongly indicates the need for rapid interventions in terms of diagnostic and treatment to prevent the spread of the pre-XDR and XDR strains and the emergence of more resistant ones.
Identifiants
pubmed: 33762833
doi: 10.2147/IDR.S289907
pii: 289907
pmc: PMC7982564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1089-1104Informations de copyright
© 2021 Cheng et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest for this work and that there is no conflict of interest regarding the publication of this paper.
Références
FEMS Microbiol Rev. 2017 May 1;41(3):354-373
pubmed: 28369307
J Clin Microbiol. 2013 Aug;51(8):2641-5
pubmed: 23761146
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):47-53
pubmed: 29297425
Infect Drug Resist. 2011;4:129-35
pubmed: 21904458
Antimicrob Agents Chemother. 2008 Aug;52(8):2937-9
pubmed: 18559646
PLoS One. 2015 Mar 27;10(3):e0120470
pubmed: 25816236
Chest. 2009 Aug;136(2):420-425
pubmed: 19349380
Int J Infect Dis. 2019 Aug;85:98-107
pubmed: 31176035
Antimicrob Agents Chemother. 2009 Nov;53(11):4835-9
pubmed: 19721073
Microbiology (Reading). 2002 Oct;148(Pt 10):2967-2973
pubmed: 12368430
Antimicrob Agents Chemother. 2015 Sep;59(9):5267-77
pubmed: 26077261
J Clin Microbiol. 2008 Aug;46(8):2692-9
pubmed: 18550737
BMC Microbiol. 2014 Jun 22;14:165
pubmed: 24953243
Ann Hum Genet. 1983 Jul;47(3):253-9
pubmed: 6614868
Evol Appl. 2018 Jun 21;11(9):1498-1511
pubmed: 30344622
Clin Infect Dis. 2008 Aug 15;47(4):450-7
pubmed: 18616396
Infect Genet Evol. 2019 Aug;72:31-43
pubmed: 30593925
Antimicrob Agents Chemother. 2003 Apr;47(4):1241-50
pubmed: 12654653
J Clin Microbiol. 1997 Apr;35(4):907-14
pubmed: 9157152
Tuberculosis (Edinb). 2017 May;104:20-23
pubmed: 28454645
Evolution. 1967 Sep;21(3):550-570
pubmed: 28563688
Infect Genet Evol. 2006 Nov;6(6):491-504
pubmed: 16632413
J Clin Microbiol. 1990 Sep;28(9):1903-5
pubmed: 2229371
BMC Infect Dis. 2018 Feb 27;18(1):98
pubmed: 29486710
BMC Infect Dis. 2019 Jan 3;19(1):3
pubmed: 30606116
Lancet Infect Dis. 2015 Oct;15(10):1193-1202
pubmed: 26116186
J Clin Microbiol. 2006 Dec;44(12):4498-510
pubmed: 17005759
J Clin Microbiol. 2007 Jun;45(6):1766-70
pubmed: 17442793
BMJ Open Respir Res. 2018 Jun 4;5(1):e000256
pubmed: 29955361
Int J Tuberc Lung Dis. 2015 Dec;19(12):1524-7
pubmed: 26614196
Antimicrob Agents Chemother. 2015 Apr;59(4):1868-75
pubmed: 25583730
Euro Surveill. 2007 May 17;12(5):E070517.1
pubmed: 17868596
BMC Infect Dis. 2011 Sep 28;11:255
pubmed: 21955640
Int J Infect Dis. 2015 Mar;32:118-23
pubmed: 25809767
N Engl J Med. 2018 Oct 11;379(15):1403-1415
pubmed: 30280646
Eur Respir J. 2017 Dec 28;50(6):
pubmed: 29284687
Clin Infect Dis. 2012 Feb 15;54(4):579-81
pubmed: 22190562
J Clin Microbiol. 2003 May;41(5):1963-70
pubmed: 12734235